Reference | </br>1:The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice. Takada I, Yogiashi Y, Makishima M.Immunobiology. 2016 Feb;221(2):188-92. doi: 10.1016/j.imbio.2015.09.008. Epub 2015 Sep 8. PMID: 26386981 </br>2:Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner. Roffé M, Lupinacci FC, Soares LC, Hajj GN, Martins VR.Cell Signal. 2015 Aug;27(8):1630-42. doi: 10.1016/j.cellsig.2015.04.004. Epub 2015 Apr 16. PMID: 25889895 </br>3:A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870. Edgar AJ, Trost M, Watts C, Zaru R.Biosci Rep. 2014 Feb 1;34(1). pii: e00091. Print 2014 Feb 1. PMID: 27919044 Free PMC Article</br>4:A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870. Edgar AJ, Trost M, Watts C, Zaru R.Biosci Rep. 2013 Dec 17. [Epub ahead of print] PMID: 24341623 </br>5:Antitumor effects of BI-D1870 on human oral squamous cell carcinoma. Chiu CF, Bai LY, Kapuriya N, Peng SY, Wu CY, Sargeant AM, Chen MY, Weng JR.Cancer Chemother Pharmacol. 2014 Feb;73(2):237-47. doi: 10.1007/s00280-013-2349-9. Epub 2013 Nov 16. PMID: 24241211 </br>6:The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1. Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S, Budach W, Stühler K, Jänicke RU.Cell Death Dis. 2013 Oct 17;4:e859. doi: 10.1038/cddis.2013.386. PMID: 24136223 Free PMC Article</br>7:BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR.Biochem J. 2007 Jan 1;401(1):29-38. PMID: 17040210 Free PMC Article
|